Julie L. Sutcliffe, Ph.D.
Director, Cyclotron and Radiochemistry Facility, Center for Molecular and Genomic Imaging
Co-Director Center for Molecular and Genomic Imaging
Professor of Medicine (Reg)
Professor of Biomedical Engineering
Locations and Contact
Clinical Interests
Dr. Sutcliffe is a researcher who develops molecular imaging agents and therapies for first-in-human studies. She currently has active trials in lung and pancreas cancer.
Research/Academic Interests
Dr. Julie Sutcliffe's research efforts bridge the spectrum of research, from benchtop discovery to clinical trials, with the goal to have a significant positive impact of the improvement of patient care and transform how we detect and treat cancer. Dr Sutcliffe’s laboratory focuses on the design, synthesis, invitro evaluation, and i in vivo screening of targeted molecular imaging agents and therapeutics, with the goal of rapid deployment to the clinic. Specifically she has focused efforts on the early detection and treatment of pancreas cancer.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.Sc., Chemistry, University of London, Leicester, England 1991
Other School
Ph.D., Medicinal Chemistry, King's College London, London, England 2002
Other School
M.Sc., Synthetic Organic Chemistry, University of London, London, England 1997
Deans’ Award for Excellence in Research, Recognized for outstanding contributions as a transformative leader in the area of Research, 2019
Most Cited Publication Award for Click for PET: Rapid Preparation... Tetrahedron Ltrs, 2006 (37) 6681-6684, 2008
Siemens "Image of the Year Award", 2007
Please click here for a list of Dr. Sutcliffe's publications.
Davis RA, Hausner SH, Harris R, Sutcliffe JL. A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide. Pharmaceutics. 2022 Mar 30;14(4):745. doi:10.3390/pharmaceutics14040745. PMID:35456579.
Kovacs L, Davis RA, Ganguly T, Chammas R, Sutcliffe JL. Repurposing an atherosclerosis targeting peptide for tumor imaging. Biomed Pharmacother. 2022 Jan;145:112469. doi:10.1016/j.biopha.2021.112469. Epub 2021 Dec 1. PMID:34864315.
Ganguly T, Bauer N, Davis RA, Hausner SH, Tang SY, Sutcliffe JL. Evaluation of Copper-64-Labeled αvβ6-Targeting Peptides: Addition of an Albumin Binding Moiety to Improve Pharmacokinetics. Mol Pharm. 2021 Dec 6;18(12):4437-4447. doi:10.1021/acs.molpharmaceut.1c00632. Epub 2021 Nov 16. PMID:34783573.
Meikle SR, Sossi V, Roncali E, Cherry SR, Banati R, Mankoff D, Jones T, James M, Sutcliffe J, Ouyang J, Petibon Y, Ma C, El Fakhri G, Surti S, Karp JS, Badawi RD, Yamaya T, Akamatsu G, Schramm G, Rezaei A, Nuyts J, Fulton R, Kyme A, Lois C, Sari H, Price J, Boellaard R, Jeraj R, Bailey DL, Eslick E, Willowson KP, Dutta J. Quantitative PET in the 2020s: a roadmap. Phys Med Biol. 2021 Mar 12;66(6):06RM01. doi:10.1088/1361-6560/abd4f7. PMID:33339012.
Ganguly T, Tang SY, Bauer N, Sutcliffe JL. Correction to: Evaluation of Two Optical Probes for Imaging the Integrin αvβ6− In Vitro and In Vivo in Tumor-Bearing Mice. Mol Imaging Biol. 2020;22:1182–1183. doi:10.1007/s11307-020-01492-x.
Krummel M, Hu K, de Vries EGE, Goetz JG, Passaro D, Subramaniam S, Misteli T, Skala M, Bravo-Cordero JJ, Sutcliffe JL. Visualizing Cancer. Cancer Cell. 2020 Dec 14;38(6):753-756. doi:10.1016/j.ccell.2020.11.014. PMID:33321083.
Foster CC, Davis RA, Hausner SH, Sutcliffe JL. αvβ6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection. J Nucl Med. 2020 Dec;61(12):1717-1719. doi:10.2967/jnumed.120.255364. Epub 2020 Sep 18. PMID:32948681.
Hausner SH, Bauer N, Davis RA, Ganguly T, Tang SYC, Sutcliffe JL. The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. Mol Imaging Biol. 2020 Dec;22(6):1543-1552. doi:10.1007/s11307-020-01500-0. PMID:32383076.